Minjin Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Minjin Wang has a total of 175 co-authors. Here are the top co-authors by number of shared publications:
- Binwu Ying
Department of Laboratory Medicine, Clinical Laboratory Medicine Research Center, West China Hospital Sichuan University, Sichuan Clinical Research Center for Laboratory Medicine Sichuan P. R. China
6 shared publications Shuo Guo
Department of Laboratory Medicine, West China Hospital of Sichuan University, Chengdu, China
6 shared publicationsYan Ren
Department of Laboratory Medicine, West China Hospital, Sichuan University , Chengdu
6 shared publicationsYang Su
Department of Laboratory Medicine, West China Hospital, Sichuan University , Chengdu
6 shared publicationsZirui Meng
Department of Laboratory Medicine, West China Hospital of Sichuan University, Chengdu, Sichuan, China
6 shared publicationsJierui Wang
Department of Neurology West China Hospital of Sichuan University Chengdu China
5 shared publications
Latest Publications
- Open Access
- 8 September 2026
- Published by Wiley in Advanced Science
Single‐Cell Profiling Reveals Clonally Expanded CX3CR1 + T Cells in Anti‐NMDA Receptor Encephalitis
Anti‐ N‐methyl‐D‐aspartate receptor encephalitis (NMDAR‐E) is a prevalent autoimmune neurological disorder, yet T cell‐driven immunopathology and its contributions to therapeutic resistance and fulminant neuroinflammation remain poorly defined. Integrative single‐cell multi‐omic profiling, combining single‐cell RNA sequencing, single‐cell T cell receptor (TCR) sequencing, and cellular indexing of transcriptomes and epitopes by sequencing, is applied to systematically map peripheral and cerebrospinal fluid (CSF) immune landscapes in treatment‐naïve NMDAR‐E patients, with orthogonal validation conducted across independent cohorts via multiparameter flow cytometry and ex vivo NR1 peptide stimulation. Clonally expanded CX3CR1‐expressing CD4 + and CD8 + T cells are identified as a core disease‐associated effector population, characterized by high predicted affinity for the pathogenic GluN1 N368/G369 epitope, robust proinflammatory and cytotoxic transcriptional programs, and enhanced intercellular crosstalk with activated B cells through major histocompatibility complex (MHC), CD99, and macrophage migration inhibitory factor signaling axes. Preferentially enriched in patient CSF, these cells produce elevated interferon‐γ (IFN‐γ) and tumor necrosis factor‐α (TNF‐α) upon antigen‐specific stimulation, collectively highlighting a disease‐associated inflammatory T cell state linked to peripheral immune activation and CNS immune remodeling, with potential translational relevance for future biomarker and therapeutic investigation.
- 8 September 2026
- Published by Wiley in Advanced Science
Open AccessSingle‐Cell Profiling Reveals Clonally Expanded CX3CR1 + T Cells in Anti‐NMDA Receptor Encephalitis
Anti‐ N‐methyl‐D‐aspartate receptor encephalitis (NMDAR‐E) is a prevalent autoimmune neurological disorder, yet T cell‐driven immunopathology and its contributions to therapeutic resistance and fulminant neuroinflammation remain poorly defined. Integrative single‐cell multi‐omic profiling, combining single‐cell RNA sequencing, single‐cell T cell receptor (TCR) sequencing, and cellular indexing of transcriptomes and epitopes by sequencing, is applied to systematically map peripheral and cerebrospinal fluid (CSF) immune landscapes in treatment‐naïve NMDAR‐E patients, with orthogonal validation conducted across independent cohorts via multiparameter flow cytometry and ex vivo NR1 peptide stimulation. Clonally expanded CX3CR1‐expressing CD4 + and CD8 + T cells are identified as a core disease‐associated effector population, characterized by high predicted affinity for the pathogenic GluN1 N368/G369 epitope, robust proinflammatory and cytotoxic transcriptional programs, and enhanced intercellular crosstalk with activated B cells through major histocompatibility complex (MHC), CD99, and macrophage migration inhibitory factor signaling axes. Preferentially enriched in patient CSF, these cells produce elevated interferon‐γ (IFN‐γ) and tumor necrosis factor‐α (TNF‐α) upon antigen‐specific stimulation, collectively highlighting a disease‐associated inflammatory T cell state linked to peripheral immune activation and CNS immune remodeling, with potential translational relevance for future biomarker and therapeutic investigation.
- Open Access
- 22 January 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (1) , e70757
Mimics and Diagnostic Pitfalls of Anti‐Adenylate Kinase 5 Limbic Encephalitis
Background: The clinical understanding of limbic encephalitis associated with antibodies against adenylate kinase 5 (AK5) remains limited. Misinterpretation of antibody test results may lead to diagnostic errors and inappropriate management. We aim to assess the frequency of anti‐AK5 encephalitis overdiagnosis and identify common diagnostic pitfalls. Methods: Cases of confirmed and mimicking anti‐AK5 limbic encephalitis from January 2021 to July 2024 using established criteria for autoimmune encephalitis (AE) were reviewed. AK5 mimics were defined as patients initially suspected of AE with a positive AK5 autoantibody result, but who ultimately received an alternative final diagnosis. Results: A total of 21 patients were included (57.1% female; median age 34 years; range 14–82). Only 3 patients (14%) were diagnosed with definite anti‐AK5 limbic encephalitis, while 18 patients (86%) were classified as AK5 mimics. Serum autoantibodies were predominantly of the IgG3 subclass, with titers ranging from 1:10 to 1:100. The mimics included primary psychiatric disorders (22%), central nervous system (CNS) infections (22%), other inflammatory disorders (28%), epilepsy (16%), neurodegenerative diseases (6%) and metabolic encephalopathy (6%). The most frequent confounding factor in misdiagnosis was the presence of prominent psychiatric and behavioral symptoms, seen in 50% (9 of 18) of AK5 mimics. The second most common confounder was the presence of low serum antibody titers or isolated serum positivity without corresponding cerebrospinal fluid (CSF) findings (< 1:100), observed in 94% (17 of 18) of mimics. Conclusion: Mimics of anti‐AK5 encephalitis are common and that misdiagnosis is often driven by non‐specific symptoms and clinically irrelevant antibody results.
- 22 January 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (1) , e70757
Open AccessMimics and Diagnostic Pitfalls of Anti‐Adenylate Kinase 5 Limbic Encephalitis
Background: The clinical understanding of limbic encephalitis associated with antibodies against adenylate kinase 5 (AK5) remains limited. Misinterpretation of antibody test results may lead to diagnostic errors and inappropriate management. We aim to assess the frequency of anti‐AK5 encephalitis overdiagnosis and identify common diagnostic pitfalls. Methods: Cases of confirmed and mimicking anti‐AK5 limbic encephalitis from January 2021 to July 2024 using established criteria for autoimmune encephalitis (AE) were reviewed. AK5 mimics were defined as patients initially suspected of AE with a positive AK5 autoantibody result, but who ultimately received an alternative final diagnosis. Results: A total of 21 patients were included (57.1% female; median age 34 years; range 14–82). Only 3 patients (14%) were diagnosed with definite anti‐AK5 limbic encephalitis, while 18 patients (86%) were classified as AK5 mimics. Serum autoantibodies were predominantly of the IgG3 subclass, with titers ranging from 1:10 to 1:100. The mimics included primary psychiatric disorders (22%), central nervous system (CNS) infections (22%), other inflammatory disorders (28%), epilepsy (16%), neurodegenerative diseases (6%) and metabolic encephalopathy (6%). The most frequent confounding factor in misdiagnosis was the presence of prominent psychiatric and behavioral symptoms, seen in 50% (9 of 18) of AK5 mimics. The second most common confounder was the presence of low serum antibody titers or isolated serum positivity without corresponding cerebrospinal fluid (CSF) findings (< 1:100), observed in 94% (17 of 18) of mimics. Conclusion: Mimics of anti‐AK5 encephalitis are common and that misdiagnosis is often driven by non‐specific symptoms and clinically irrelevant antibody results.
- 2 December 2025
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 119 (5) , 447-448
Reevaluating CV2/CRMP5 positivity as a marker of immune transition in parenchymal neurosyphilis—authors’ reply
- 2 December 2025
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 119 (5) , 447-448
Reevaluating CV2/CRMP5 positivity as a marker of immune transition in parenchymal neurosyphilis—authors’ reply
- 22 October 2025
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 119 (3) , 205-215
CV2/CRMP5 antibodies are specifically associated with parenchymal neurosyphilis: a retrospective cohort study
Background: Neurosyphilis can trigger neuro-specific immune responses, but evidence remains scarce. This study investigates the prevalence and clinical significance of neural antibodies in neurosyphilis, with a focus on CV2/CRMP5 antibodies. Methods: We retrospectively analyzed 1149 patients with syphilitic neurological symptoms. Of 247 diagnosed with neurosyphilis, 215 met inclusion criteria. Using CBA and line blot, 97 patients suspected of autoimmune encephalitis were tested for neural antibodies, with positives confirmed by in-house CBA. Complete medical records were collected. Homology between CV2/CRMP5 and Treponema pallidum was assessed via BLAST and structural modeling. Results: Twenty neurosyphilis patients were positive for neural antibodies. Antibodies against neuronal intracellular antigens (NIA-abs) predominated (15/20, 75%), with CV2/CRMP5 being the most frequent (73.3% of NIA-abs). Critically, all CV2/CRMP5-positive cases (11/11, 100%) had parenchymal neurosyphilis (p-NS), and none were found in 86 asymptomatic neurosyphilis (a-NS) patients. In the prospective validation cohort of 115 p-NS patients, 8 CV2/CRMP5-positive cases were identified. Combining retrospective and prospective data, the serum positivity rate of CV2/CRMP5 antibodies in p-NS was 9.79%. These patients exhibited significantly higher serum Toluidine Red Unheated Serum Test (TRUST) titers (median 1:64 vs. 1:16, P < 0.001) and elevated cerebrospinal fluid Immunoglobulin G (CSF IgG) indices (median 2.90 vs. 2.06, P = 0.005) compared to CV2/CRMP5-negative p-NS patients. No homology between CV2/CRMP5 and Treponema pallidum proteins was found. Conclusion: Our study identifies a strong association between CV2/CRMP5 antibodies and p-NS. Screening for these antibodies is recommended for p-NS patients, especially those with high serum TRUST titers and intrathecal immunoglobulin synthesis, as they may represent a subgroup with distinct immunopathological mechanisms.
- 22 October 2025
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 119 (3) , 205-215
CV2/CRMP5 antibodies are specifically associated with parenchymal neurosyphilis: a retrospective cohort study
Background: Neurosyphilis can trigger neuro-specific immune responses, but evidence remains scarce. This study investigates the prevalence and clinical significance of neural antibodies in neurosyphilis, with a focus on CV2/CRMP5 antibodies. Methods: We retrospectively analyzed 1149 patients with syphilitic neurological symptoms. Of 247 diagnosed with neurosyphilis, 215 met inclusion criteria. Using CBA and line blot, 97 patients suspected of autoimmune encephalitis were tested for neural antibodies, with positives confirmed by in-house CBA. Complete medical records were collected. Homology between CV2/CRMP5 and Treponema pallidum was assessed via BLAST and structural modeling. Results: Twenty neurosyphilis patients were positive for neural antibodies. Antibodies against neuronal intracellular antigens (NIA-abs) predominated (15/20, 75%), with CV2/CRMP5 being the most frequent (73.3% of NIA-abs). Critically, all CV2/CRMP5-positive cases (11/11, 100%) had parenchymal neurosyphilis (p-NS), and none were found in 86 asymptomatic neurosyphilis (a-NS) patients. In the prospective validation cohort of 115 p-NS patients, 8 CV2/CRMP5-positive cases were identified. Combining retrospective and prospective data, the serum positivity rate of CV2/CRMP5 antibodies in p-NS was 9.79%. These patients exhibited significantly higher serum Toluidine Red Unheated Serum Test (TRUST) titers (median 1:64 vs. 1:16, P < 0.001) and elevated cerebrospinal fluid Immunoglobulin G (CSF IgG) indices (median 2.90 vs. 2.06, P = 0.005) compared to CV2/CRMP5-negative p-NS patients. No homology between CV2/CRMP5 and Treponema pallidum proteins was found. Conclusion: Our study identifies a strong association between CV2/CRMP5 antibodies and p-NS. Screening for these antibodies is recommended for p-NS patients, especially those with high serum TRUST titers and intrathecal immunoglobulin synthesis, as they may represent a subgroup with distinct immunopathological mechanisms.
- 24 June 2025
- Published by Wiley in Annals of Neurology
- Vol. 98 (4) , 750-761
Clinical and Genetic Findings in a Chinese Cohort of Dentatorubral–Pallidoluysian Atrophy Patients
Objective: Dentatorubral–pallidoluysian atrophy (DRPLA) is a rare, inherited neurodegenerative disorder caused by the expansion of cytosine–adenine–guanine repeats in ATN1 . Most studies on DRPLA to date are limited to case reports. We aimed to provide a comprehensive summary of the clinical, genetic, biological, and magnetic resonance imaging characteristics of DRPLA using cross‐sectional baseline data. Methods: This is a cross‐sectional observational cohort study. We used an extensive battery of assessments, included clinical phenotypes, genotypes, cognitive performance, biological markers, and magnetic resonance imaging characteristics. Results: We enrolled 116 DRPLA patients, including 96 manifest patients and 20 prodromal patients. We identified a previously unreported ATN1 haplotype consisting of 8 single‐nucleotide polymorphisms. Cognitive assessments revealed that 51 manifest patients (96%) and 4 prodromal patients (29%) scored P < 0.001) and healthy controls ( P < 0.001). Magnetic resonance imaging findings revealed widespread gray matter loss across the whole brain in manifest patients, whereas prodromal patients showed gray matter loss localized to the bilateral cerebellar hemispheres. Interpretation: This is the first DRPLA cohort study to comprehensively report clinical, genetic, cognitive, imaging, and plasma neurofilament light data. This study provides robust data to enhance our understanding of the overall features of DRPLA. We also propose clear definitions for the preclinical stage of DRPLA, and demonstrate the high diagnostic utility of plasma neurofilament light as a biomarker. ANN NEUROL 2025;98:750–761
- 24 June 2025
- Published by Wiley in Annals of Neurology
- Vol. 98 (4) , 750-761
Clinical and Genetic Findings in a Chinese Cohort of Dentatorubral–Pallidoluysian Atrophy Patients
Objective: Dentatorubral–pallidoluysian atrophy (DRPLA) is a rare, inherited neurodegenerative disorder caused by the expansion of cytosine–adenine–guanine repeats in ATN1 . Most studies on DRPLA to date are limited to case reports. We aimed to provide a comprehensive summary of the clinical, genetic, biological, and magnetic resonance imaging characteristics of DRPLA using cross‐sectional baseline data. Methods: This is a cross‐sectional observational cohort study. We used an extensive battery of assessments, included clinical phenotypes, genotypes, cognitive performance, biological markers, and magnetic resonance imaging characteristics. Results: We enrolled 116 DRPLA patients, including 96 manifest patients and 20 prodromal patients. We identified a previously unreported ATN1 haplotype consisting of 8 single‐nucleotide polymorphisms. Cognitive assessments revealed that 51 manifest patients (96%) and 4 prodromal patients (29%) scored P < 0.001) and healthy controls ( P < 0.001). Magnetic resonance imaging findings revealed widespread gray matter loss across the whole brain in manifest patients, whereas prodromal patients showed gray matter loss localized to the bilateral cerebellar hemispheres. Interpretation: This is the first DRPLA cohort study to comprehensively report clinical, genetic, cognitive, imaging, and plasma neurofilament light data. This study provides robust data to enhance our understanding of the overall features of DRPLA. We also propose clear definitions for the preclinical stage of DRPLA, and demonstrate the high diagnostic utility of plasma neurofilament light as a biomarker. ANN NEUROL 2025;98:750–761
- 7 January 2025
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 118 (4) , 300-302
Post-kidney transplantation EBV-related brainstem encephalitis
- 7 January 2025
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 118 (4) , 300-302
Post-kidney transplantation EBV-related brainstem encephalitis
- 14 November 2024
- Published by Wiley in Journal of Medical Virology
- Vol. 96 (11) , e70050
Epidemiological Characteristics of Neuro‐Specific Antibodies Following Viral Infections
This study aims to explore the epidemiological characteristics of neuro‐specific antibodies (ns‐Ab) induced by different viral infections within the central nervous system (CNS). Additionally, it seeks to compare the autoimmune effects following several typical viral infections in CNS. We conduct a retrospective study to compare and analyze the prevalence trends of ns‐Ab in patients with different viral infections. Additionally, evaluate the intensity of CNS inflammatory responses postviral infection by correlating clinical characteristics and laboratory findings, and briefly demonstrate the immune effects in CNS following various viral infections. This study retrospectively collected data from 1037 patients hospitalized with suspected CNS infections. A total of 654 patients (63.1%) were included in the final analysis. A higher proportion of patients with pathogens present in their cerebrospinal fluid (CSF) (114 out of 332, 34.3%) tested positive for ns‐Ab compared to those without pathogens (70 out of 322, 21.7%) ( p = 0.0004). Specifically, the screening rate for ns‐Ab in patients with CNS viral infections (83 out of 165, 50.3%) and the prevalence of ns‐Ab (27 out of 83, 32.5%) were significantly higher than in those with other pathogen infections ( p < 0.0001 and p = 0.016, respectively). Among these, human herpesvirus 7 (HHV7) patients had the highest detection rate of ns‐Ab during the disease course (11 out of 26, 42.3%), but exhibited infection characteristics distinctly different from those of herpes simplex virus 1 (HSV1). Viral infections significantly promote the development of autoimmune responses in CNS. The production of ns‐Ab and the subsequent autoimmune response vary across different viral infections. There is a strong statistical correlation between HHV7 and the presence of ns‐Ab, suggesting that HHV7 may serve as an early indicator of secondary autoimmune response following CNS infections.
- 14 November 2024
- Published by Wiley in Journal of Medical Virology
- Vol. 96 (11) , e70050
Epidemiological Characteristics of Neuro‐Specific Antibodies Following Viral Infections
This study aims to explore the epidemiological characteristics of neuro‐specific antibodies (ns‐Ab) induced by different viral infections within the central nervous system (CNS). Additionally, it seeks to compare the autoimmune effects following several typical viral infections in CNS. We conduct a retrospective study to compare and analyze the prevalence trends of ns‐Ab in patients with different viral infections. Additionally, evaluate the intensity of CNS inflammatory responses postviral infection by correlating clinical characteristics and laboratory findings, and briefly demonstrate the immune effects in CNS following various viral infections. This study retrospectively collected data from 1037 patients hospitalized with suspected CNS infections. A total of 654 patients (63.1%) were included in the final analysis. A higher proportion of patients with pathogens present in their cerebrospinal fluid (CSF) (114 out of 332, 34.3%) tested positive for ns‐Ab compared to those without pathogens (70 out of 322, 21.7%) ( p = 0.0004). Specifically, the screening rate for ns‐Ab in patients with CNS viral infections (83 out of 165, 50.3%) and the prevalence of ns‐Ab (27 out of 83, 32.5%) were significantly higher than in those with other pathogen infections ( p < 0.0001 and p = 0.016, respectively). Among these, human herpesvirus 7 (HHV7) patients had the highest detection rate of ns‐Ab during the disease course (11 out of 26, 42.3%), but exhibited infection characteristics distinctly different from those of herpes simplex virus 1 (HSV1). Viral infections significantly promote the development of autoimmune responses in CNS. The production of ns‐Ab and the subsequent autoimmune response vary across different viral infections. There is a strong statistical correlation between HHV7 and the presence of ns‐Ab, suggesting that HHV7 may serve as an early indicator of secondary autoimmune response following CNS infections.
- Open Access
- 11 November 2024
- Published by Wiley
Advancements in misfolded prion protein detection
Prion diseases are fatal, progressive, transmissible neurodegenerative conditions that affect both humans and animals. The scrapie prion protein (PrPSc), a misfolded form of prion, is both the cause of prion diseases and gold standard biomarker for diagnosis. Given the infectivity and 100% lethality of prions, new detection methods are urgently needed to enhance the diagnosis and surveillance of prion diseases. In this review, we summarize recent advancements in PrPSc detection. We explore in vitro seeding assays, such as Protein Misfolding Cyclic Amplification and Real-Time Quaking-Induced Conversion, alongside innovative biosensors and imaging techniques developed for prion detection. This review highlights the evolving landscape of PrPSc detection methods and their potential roles in early diagnosis, prion transmission control, and effective treatment development.
- 11 November 2024
- Published by Wiley
Open AccessAdvancements in misfolded prion protein detection
Prion diseases are fatal, progressive, transmissible neurodegenerative conditions that affect both humans and animals. The scrapie prion protein (PrPSc), a misfolded form of prion, is both the cause of prion diseases and gold standard biomarker for diagnosis. Given the infectivity and 100% lethality of prions, new detection methods are urgently needed to enhance the diagnosis and surveillance of prion diseases. In this review, we summarize recent advancements in PrPSc detection. We explore in vitro seeding assays, such as Protein Misfolding Cyclic Amplification and Real-Time Quaking-Induced Conversion, alongside innovative biosensors and imaging techniques developed for prion detection. This review highlights the evolving landscape of PrPSc detection methods and their potential roles in early diagnosis, prion transmission control, and effective treatment development.
- 10 November 2024
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (3) , 1439-1441
KLHL11-associated rhomboencephalitis presenting as clippers-like syndrome
- 10 November 2024
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (3) , 1439-1441
KLHL11-associated rhomboencephalitis presenting as clippers-like syndrome
- 1 May 2024
- Published by American Medical Association (AMA) in JAMA Neurology
- Vol. 81 (5) , 554
Discussion on the Application of Rapid Immunoblot Assay for AQP4-IgG Detection
To the Editor We read with great interest the research finding by Fu et al, which presents a novel immunodot assay that is both highly efficient and user friend
- 1 May 2024
- Published by American Medical Association (AMA) in JAMA Neurology
- Vol. 81 (5) , 554
Discussion on the Application of Rapid Immunoblot Assay for AQP4-IgG Detection
To the Editor We read with great interest the research finding by Fu et al, which presents a novel immunodot assay that is both highly efficient and user friend